Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Immunovant Inc (IMVT) USD0.0001

Sell:$49.07 Buy:$49.17 Change: $0.64 (1.28%)
Market closed |  Prices as at close on 30 November 2020 | Switch to live prices |
Change: $0.64 (1.28%)
Market closed |  Prices as at close on 30 November 2020 | Switch to live prices |
Change: $0.64 (1.28%)
Market closed |  Prices as at close on 30 November 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunovant, Inc., formerly Health Sciences Acquisitions Corp, is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. It is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn).

Contact details

320 West 37Th Street
United States
+1 (917) 5803099

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.88 billion
Shares in issue:
97.89 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Frank Torti
    Chairman of the Board
  • Peter Salzmann
    Chief Executive Officer, Director
  • Pamela Connealy
    Chief Financial Officer
  • Julia Butchko
    Chief Development and Technology Officer
  • Michael Elliott
    Chief Scientific Officer
  • W. Bradford Middlekauff
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.